Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838979 | 1.00 | P2RX7 (0.45) | P2RX7CNR1CNR2CCNA2CDK2 | |
| SCHEMBL6256315 | 0.84 | HSD17B1 (0.43) | P2RX7CNR1CNR2CCNA2CDK2 | |
| SCHEMBL5838554 | 0.84 | HSD17B1 (0.49) | P2RX7CNR1CNR2CCNA2CDK2 | |
| SCHEMBL5838675 | 0.82 | P2RX7 (0.46) | P2RX7CNR1CNR2HPGDSMN1; SMN2 | |
| SCHEMBL5838995 | 0.82 | P2RX7 (0.46) | P2RX7CNR1CNR2HPGDSMN1; SMN2 | |
| SCHEMBL5838150 | 0.82 | P2RX7 (0.52) | P2RX7CNR1CNR2SMYD3 | |
| SCHEMBL1412889 | 0.81 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL1412974 | 0.81 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL5837838 | 0.79 | P2RX7 (0.40) | P2RX7CNR1CNR2SMYD3HPGD | |
| SCHEMBL5839340 | 0.79 | P2RX7 (0.41) | P2RX7CNR1CNR2CDK2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | DOMBROSKI MARK A | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885CNR1 62/4885CNR2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.